A first-in-human trial of deep brain stimulation (DBS) for post-stroke rehabilitation patients by Cleveland Clinic researchers has shown that using DBS to target the dentate nucleus – which regulates fine-control of voluntary movements, cognition, language, and sensory functions in the brain – is safe and feasible.
TerrAscend Q1 Revenue Lifts 1% Sequentially to $69.4 Million
TerrAscend Reports Record First Quarter 2023 Revenue First quarter 2023 record Net Revenue of $69.4 million, an increase of 42.8% year-over-year 6th consecutive quarter of
May 12, 2023